Unicycive Therapeutics Inc (UNCY) FinancialsUNCYUnicycive Therapeutics Inc

Evaluating the bottom line, Unicycive Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -101.07%, provide a clear picture of how effectively UNCY converts its operational activities into shareholder value.

In the context of the broader market, UNCY competes directly with industry leaders such as VYGR and BDTX. With a market capitalization of $96.95M, it holds a significant position in the sector. When comparing efficiency, UNCY's gross margin of N/A stands against VYGR's 100.00% and BDTX's N/A. Such benchmarking helps identify whether Unicycive Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown significant losses, with a net income of -21,525,000 USD in Q4 2024 and a gross profit of 0 USD in multiple quarters, indicating financial instability.